UroGen Pharma (URGN) Other Working Capital Changes (2017 - 2026)
UroGen Pharma's (URGN) quarterly Other Working Capital Changes came in at -$53000.0 in Q1 2026, up 92.82% YoY from -$27487.0 in Q1 2025, and down 103.98% on a QoQ basis from $1.3 million in Q4 2025.
UroGen Pharma (URGN) Other Working Capital Changes (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 6 years of Other Working Capital Changes data on file, last reported at -$53000.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 92.82% year-over-year to -$53000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46000.0 (up 103.02% YoY) and the FY2025 annual result came in at -$639000.0, up 38.2% from the prior year.
- Other Working Capital Changes declined to -$53000.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $4.9 million in Q1 2026 to a low of -$5.8 million in Q4 2023.
- A 5-year average of $709117.6 and a median of $1.0 million in 2023 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 426.72% in 2025, down 241.3% in 2025.
- Tracing URGN's Other Working Capital Changes over 5 years: stood at -$269000.0 in 2022, then climbed by 17.84% to -$221000.0 in 2023, then slumped by 84.62% to -$408000.0 in 2024, then surged by 426.72% to $1.3 million in 2025, then slumped by 103.98% to -$53000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$53000.0 (Q1 2026), $1.3 million (Q4 2025), and -$628000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.75 Mn |
| Jun 30, 2026 | -6.75 Mn |
| Jun 30, 2026 | -6.75 Mn |
| Mar 31, 2026 | 4.86 Mn |
| Mar 31, 2026 | 4.86 Mn |
| Mar 31, 2026 | 4.86 Mn |
| Dec 31, 2025 | 2.55 Mn |
| Dec 31, 2025 | 2.55 Mn |
| Dec 31, 2025 | 2.55 Mn |
| Sep 30, 2025 | 67,000.00 |
| Sep 30, 2025 | 67,000.00 |
| Sep 30, 2025 | 67,000.00 |
| Jun 30, 2025 | -928,000.00 |
| Jun 30, 2025 | -928,000.00 |
| Jun 30, 2025 | -928,000.00 |
| Mar 31, 2025 | 4.14 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Dec 31, 2024 | -5.21 Mn |
| Dec 31, 2024 | -5.21 Mn |